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ABSTRACT
We describe the synthesis of 2'-O-methyl, 2'-O-ethyl
oligoribonucleotides and phosphorothioate oligodeoxy-
ribonucleotides and demonstrate their utility as
Inhibitors of the in vitro U7 snRNP-dependent mRNA
processing event. These 2'-O-modifled compounds
were designed to possess the binding affinity of an
RNA molecule towards a complementary RNA target
with an enhanced stability against nucleases. The 2-0-
methyl and 2'-0-ethyl antisense compounds function
as potent inhibitors of the reaction at 1-10 nM,
approximately 5-fold more effective than a natural
antisense RNA molecule and requiring an approximate
5-fold excess over the target RNA for 80% inhibition
of the processing reaction.
INTRODUCTION
The use of synthetic oligonucleotides as specific inhibitors of gene
expression has attracted molecular biologists' attentions.
However, a major limit to the application of this strategy can
be traced to the biological instability of short, single-stranded
DNA molecules when they enter the living cell. An approach
to reduce this bioerosion has been to synthesize unnatural nucleic
acid analogs which continue to possess the inhibitory activity of
natural nucleic acids yet have enhanced biostability. We are in
the process of developing modified synthetic RNA molecules.
Because the RNA-RNA duplex is more stable than the DNA-
RNA hybrid, we have focused our attention on this sort of hybrid.
However, in return for an increased hybrid stability, the chemical
properties of RNA carries a high price in increased susceptibility
to nuclease degradation. To counter this phenomenon we have
investigated RNA oligonucleotides prepared from nucleotides
which possess modifications at the 2' hydroxyl group, as a method
of blocking at least one class of nucleases. We report here the
biological inhibitory activity of two of these nucleic acid analogs,
the 2'-O-methyl and 2'-O-ethyl derivatives of RNA.
We are studying the control of histone mRNA biosynthesis. •
One of the major control points in this complex synthesis pathway
is the interaction of the U7 small nuclear ribonucleoprotein
(snRNP) with the histone precursor mRNA. This interaction is
required for endonucleolytic cleavage of the pre-mRNA to
generate a mature-sized mRNA which is then transported to the
cytoplasm (1). The 15-20 nucleotides near the 5' end of the
U7 RNA include complementarities (Figure 1) to the histone pre-
mRNA sequence (2 -5 ) and these complementarities are essential
for the processing event (3-7). Furthermore, it has been
demonstrated, that during the cell cycle the accessibility of these
same 5' nucleotides of the U7 snRNP are modulated by the cell
in concert with DNA synthesis (8, 9). Because the processing
of histone pre-mRNA by the U7 snRNP plays an important role
in the cell cycle control of histone biosynthesis, we have
developed an in vitro system for reproducing this processing event
(10). This system uses a nuclear extract from rapidly dividing
mammalian cells as a source of the processing factors (primarily
the snRNP U7, see (11, 12). When a radioactive RNA molecule
containing the processing signals of a histone pre-mRNA is added
to this extract, a specific cleavage of the pre-mRNA occurs to
generate a molecule identical to the in vivo cleaved product (10).
Because this cleavage event requires the basepairing interaction
between the U7 snRNP and the pre-mRNA (6) and the sequence
of the U7 RNA is known (3—5), we have designed
oligonucleotides (Figure 1) complementary to either the pre-
mRNA or the U7 snRNA which, upon binding to their target
sequence, interfere with the processing event (7). We have
previously used this test system to compare the inhibitory activity
of various natural RNA and DNA antisense molecules and
ribozymes targeted to the U7 sequence (7, 13).
GENERAL METHODS
Abbreviations: DBU: l,8-diazabicyclo[5.4.0]undec-7-ene;
DMAP: 4-(N,N-dimethylamino)pyridine; DMTr: dimethoxy-
trityl; DTT: dithiothreitol; EDTA: ethylenediaminetetraacetic
acid; HEPES: 2-[4-(2-hydroxyethyl)-l-piperazinyl]-ethane-
sulfonic acid; MMTr: monomethoxytrityl; NPE: 2-(4-nitro-
phenyl)ethyl; PMSF: phenylmerhylsulfonyl fluoride; RP-HPLC:
reverse phase-HPLC; SDS: dodecylsulfonate Na-salt; TBE: 89
mM Tris, 89 mM borate, 0.1 mM EDTA buffer; TEAA: tetra-
ethylammonium acetate buffer.
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Figure 1. The sequences used in these experiments. The U7 sequence and the
mouse histone H4 prc-mRNA have been described previously (7). The U7 RNA
probably functions through a basepairing interaction with the purine-nch element
in the pre-mRNA. The sequences of 7U 19mer (as 2'-O-methyl and 2'-O-ethyl
RNA) and 7U 18mer DNA, the control 2'-O-methyl oligonucleotkte NS19mer
(with no complementarities to U7), and the antisense U7 RNA 63mer (with
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Nuclear extracts (14) were prepared from mouse EBI cells (4)
and in vitro histone procession reactions were performed as
previously described (10) using an abbreviated mouse histone
H4 RNA substrate (12).
Synthesis of normal antisense U7-RNA (7U) was performed
by in vitro T7 polymerase transcription of a derivative of pTZ19
(Pharmacia) containing a mouse U7 sequence insert derived from
synthetic DNA oligonucleotides (7).
Synthesis of the oligonucleotides
Oligodeoxynucleotides: DNA synthesis was performed on an ABI
380 B DNA-synthesizer (Applied Biosystems) using standard
methodology (15). The oligodeoxynucleotide was purified by
ethanol precipitation and denaturing polyacrylamide gel
electrophoresis.
2 '-O-Methyl oligoribonucleotides: The 19mer 2'-methoxy oligo-
nucleotides were synthesized on an ABI 380 B DNA-synthesizer
using controlled-pore glass (CPG) solid support with a starting
3'-deoxynucleoside. 2'-O-Methyl nucleoside (2-cyanoethyl)-N,N-
diisopropylphosphoramidites with the following protecting groups
were used: A: N6-phenoxyacetyl, 5'-O-DMTr; C: N4-benzoyl,
5'-O-MMTr; G: N2-phenoxyacetyl, 5'-O-DMTr; U: 5'-O-
MMTr (16). Standard DNA methodology with increased coupling
time (5 min instead of 3 min) was used. The oligonucleotide was
deprotected and cleaved from the solid support with 25 % aqueous
NH4OH soln (15 h 55°C). After final detritylation the crude
oligonucleotide was purified by denaturing polyacrylamide gel
electrophoresis. For U7 inhibition, an aliquot was further purified
on RP-HPLC (Fig. 2).
Phosphorothioate oligodeoxynucleotides: The synthesis of the
phosphorothioate was accomplished by H-phosphonate
methodology on an ABI 380 B DNA-synthesizer using the
recommended procedures (17—19). The sulfurization was carried
out with sulfur (5% in carbondisulfide, pyridine, triethylamine
12:12:1) on the solid support with the 5'-end still protected. After
cleavage from the support and deprotection of the bases, the
5'-trityl phosphorothioate oligonucleotide was purified by RP-
Flgure 2. HPLC profiles (UV-detection 260 nm) of 2'-O-methyl-7U 19mer,
NrtG-2'-O-ethyl-7U 19mer, 2'-O-ethyl-7U 19mer; column: 4x250 mm
Nucleosil 100-5 C18 M6, gradient: 100 mM TEAA pH=6.5, 0.1 mM EDTA,
10-40 min 0-40%, 40-60 min 40-100% acetonitrile.
HPLC. The main peak material was detritylated and again
subjected to RP-HPLC purification.
2 '-O-Ethyl oligoribonucleotides: The synthesis was performed
on a Pharmacia Gene Assembler loaded with 0.2 /imol solid
support (5 /im polystyrene based polymer-beads) with
deoxythymidine as the 3'-starting nucleotide. 2'-O-Ethyl
nucleoside (2<yaiKiemyi)-N,N-diisopropylphosphoiairiidites with
the following protecting groups were used: A:
N*-phenoxyacetyl, 5'-O-DMTr; C: N4-benzoyl, 5'-O-DMTr;
G: N^phenoxyacetyl, O6-NPE, 5'-O-DMTr; U: 5'-O-DMTr
(16). The coupling conditions were as recommended for standard
DNA-synthesis except for the coupling time, which was extended
to 5 min (deprotection: 0.4 min 3% trichloroacetic acid in
dichloroethane; coupling: 5.0 min 25 equiv. amidite, 500 equiv.
tetrazole in acetonitrile; capping: 0.4 min 10% acetic anhydride,
3% 4-(N,N-dimethylamino)pyridine (DMAP), 15% collidine in
acetonitrile; oxidation: 0.1 min 0.01 M I2, 5% collidine in
aqueous acetonitrile). This was necessary to counteract the
reduced coupling efficiency due to steric hindrance by the bulky
3'-ethoxy group. The mean coupling efficiency was 98.3%
(calculated from the amount of released tritylcation during
deprotection). Base deprotection and purification: After final
detritylation the bound oligonucleotide was treated with 25%
aqueous ammonia for 2 h at 55 °C to cleave it from the support
and to remove all protecting groups except the
O6-2-(4-nitrophenyl)ethyl (NPE) group of guanosine. The
solution was evaporated in vacuo and part of the crude NPE
protected oligonucleotide was purified on RP-HPLC (Fig. 2) to
serve as a negative control for the inhibition studies. To remove
the NPE group, the oligonucleotide was treated for 24 h with
500 /tl of IM DBU in pyridine at 55°C (20). After neutralization
of the DBU with 1.1 equivalents of acetic acid and partial
evaporation in vacuo, the yellow solution was subjected to gel
Nucleic Acids Research, Vol. 19, No. 10 2631
NORMAL RNA 2 - O - methyl RNA
Imol
i M i 1 , 2 , 3 i 4 i 5 , 6 i 7 i 8 i 9 , 10 i 11 i 12 i 13 i 14 i M
proc. —
36-
Flgure 3. Comparison of 2'-O-methyl 19mer vs. 7U RNA. Lane 1, unreacted
substrate; lane 2, control processing reaction; lanes 3 - 6 , processing after a
preincubation with 3, 30, 300, or 3000 fmoles 7U RNA; lanes 7 -11 , processing
after a preincubation with 3, 30, 300, 3000, or 30,000 fmoles 2'-O-methyl-7U
19mer; lane 12, 300 fmoles of 2'-0-methyl-7U 19mer were preincubated with
3 pmoles U7 RNA (in buffer D) before addition to nuclear extract; lane 13, the
nuclear extract was preincubated with 300 fmoles 2'-O-methyl-7U 19mer,
afterwards, 3 pmoles of U7 RNA were added to the reaction; lane 14, control
processing reaction; the addition of 3 pmoles U7 RNA has no effect on the
processing reaction (7); lanes M, molecular weight standards: HpaTJ-cut pBR322
"P-labeled with the Klenow fragment of polymerase I and or- 2P-dCTP, with
the size of some of the fragments indicated to the left of the figure. The
abbreviations sub. and proc. indicate the positions of the pre-mRNA substrate,
and the processed product.
filtration and the product was further purified by preparative
polyacrylamide gel electrophoresis. The yield of purified 19mer
was 240 ng (36 pmol, 18% based on the solid support, RP-HPLC
profile Fig. 2).
Inhibition of processing
In general, the inhibition assays were performed as previously
described (7). A 7.5 or 15 /J aliquot of nuclear extract (in buffer
D: 0.1 M KC1, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF,
20% glycerol, 20 mM Hepes, pH 7.4) from a mouse hybridoma
line (containing approximately 3 or 6 fmoles of U7 RNA) was
preincubated with the test oligo in the presence of 5 mM MgCl2
(in a volume of 15 /tl) for 30 minutes on ice, 30 minutes at room
temperature followed by 30 minutes at 30°C. After this
preincubation, 15 /tl of a reaction mixture containing tRNA,
RNasin, EDTA (to final concentrations of 0.17 mg/ml, 400
units/ml and 20 mM) and approximately 10 fmoles (10,000 CPM)
of a ^P-labeled histone pre-mRNA were added to the sample.
The reaction was allowed to proceed at 30°C for 2 hours, then
proteinase K and SDS were added to 0.5 mg/ml and 0.5%
respectively and the samples were incubated at 37 °C for 30
minutes. The RNA from the sample was then treated with
phenol/chloroform, precipitated with ethanol, dissolved in 80%
formamide/0.5xTBE plus 0.025% bromphenol blue & 0.025%
xylene cyanol and resolved on a preheated 10.7% acrylamide/8.3
M urea/TBE gel. The resulting radioactive pattern was visualized
by exposure of X-ray film at -70°C. Various modifications of
this protocol are described in individual figure legends.
RESULTS
The experiments were designed to test the efficiency of various
oligonucleotide inhibitors of U7 function. We have previously
shown that the 20 nucleotides at the 5'-end of the active U7
snRNP are accessible to micrococcal nuclease digestion (7, 8,
21) and that complexing these 5' nucleotides with a
complementary RNA oligonucleotide or removing them with a
coupled deoxyoligo binding/RNase H cleavage, blocks the
processing reaction (7). We found that the most potent inhibitor
of the reaction (on a molar basis) was an antisense RNA molecule
complementary to 61 nt of the 63 nt U7 sequence and a major
limit to the function of antisense inhibitors was rapid degradation
of the inhibitor in the nuclease-rich extracts used for these
experiments. Therefore, we sought to develop small
oligonucleotides which incorporated the high binding affinity of
an RNA molecule yet had enhanced resistance to nucleases.
Modification of the ribose by the attachment of a 2'-O-methyl
group blocks the action of both RNA- and DNA-specific
nucleases (22-26). Therefore, we and others (22, 27-31 ,
38-40) have developed synthetic chemistry techniques which
allow the synthesis of oligoribonucleotides bearing 2'-O-methyl
modification. We have also produced 2'-O-ethyl modified RNA
molecules with the idea that increased lipophilicity may both
increase the stability against nucleases and enhance the
intracellular uptake of the resulting oligoribonucleotides.
Natural 63mer antisense RNA versus 2'-O-methyl 19mer
antisense RNA
For an initial test of a 2'-O-methyl oligoribonucleotide's inhibitory
capacity, we compared processing inhibition between a 19
nucleotide 2'-O-methyl RNA molecule (2'-O-methyl-7TJ 19mer)
and a naturally-synthesized RNA molecule containing the
complement to 61 nt of the U7 sequence (7U RNA). In previous
studies, we found this antisense RNA to be the most efficient
inhibitor of in vitro processing, blocking the reaction completely
when present at a 30-fold molar excess over the U7 RNA (7).
Correspondingly the presence of 300 fmoles of 7U RNA blocks
approximately 95 % of the processing activity and 30 fmoles gives
a partial reduction (Figure 3, lanes 2—5). In comparison, the
2'-O-methyl-7U 19mer functions to give complete inhibition at
300 fmoles and approximately 80% inhibition at 30 fmoles
(Figure 3, lanes 6-10). As a control, the 2'-O-methyl-7U 19mer
was prehybridized to a 10-fold excess of U7 RNA before adding
it to the nuclear extract. We find that this maneuver results in
a complete block of the inhibition (Figure 3, lane 12), which,
with 300 fmoles of 2'-O-methyl-7U 19mer alone, is complete
(Figure 3, lane 9). This demonstrates that the 2'-O-methyl
inhibitor is functioning via base-pair hybridization with the target
RNA and the inhibition is not due to unspecific effects. When
the complement to the inhibitor is added after a preincubation
of the inhibitor with the extract, we previously found that
inhibition by antisense RNA could be reversed (7). When this
same experiment is repeated with the 2'-O-methyl inhibitor, we
find that only a small portion of the inhibition can be reversed
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Figure 4. 2'-O-Methyl-7U 19mer vs. thioateDNA 7U 19mer. Lane 1, unreacted
substrate; lane 2, control processing reaction; lane 3, processing reaction pretreated
with magnesium; lanes 4—7, processing after a preincubation with 3, 30, 300,
or 3000 fmoles 2'-O-methyl-7U 19mer; lane 8, processing after preincubation
with 3 pmoles of a control 2'-O-methyl 19mer; lanes 9 -13 , processing after
a preincubation with 0.3, 3, 30, 300, 3000, fmoles thioateDNA 7U 19mer; lane
14, control processing reaction, lane M, molecular weight standards as in Figure 1.
(Figure 3, lane 13). The cause and consequences of this
phenomenon will be discussed below.
Phosptaorothioate antisense DNA 19mer vs. 2'-O-methyl
antisense RNA 19mer
We next tested a phosphorothioate DNA derivative of the 7U
19mer oligonucleotide. If the sole determinant of the enhanced
inhibition by the 2'-O-methyl RNA molecule is due to stability
against nucleases, then the use of a phosphorothioate derivative
of the 7U 19mer oligonucleotide should also show an enhanced
inhibition capacity. However, along with the increased nuclease
resistance, the phosphorothioate modification displays a decreased
binding affinity to its complement due to stereochemical
considerations (see reference 32 for a discussion of this
phenomenon). We tested, in the histone processing reaction, the
inhibitory capacity of a phosphorothioate DNA 7U 19mer vs.
the 2'-O-methyl-7U 19mer shown previously (Figure 3). Once
again we find that the 2'-O-methyl-7U 19mer completely inhibits
at 300 fmoles and inhibits to approximately 80% at 30 fmoles
(Figure 4, lanes 4 -7) . We have included a sample with a control,
nonsense 2'-O-methyl oligo, a 19mer with no complementarities
to U7. This oligo (NS19mer) has no effect on the processing
reaction when 3 pmoles are added to the reaction (Figure 4, lane
8). When the phosphorothioate DNA 7U 19mer is tested in this
system, we find that minor inhibition of the reaction occurs at
300 fmoles and approximately 30% inhibition can be seen at 3
pmoles (Figure 4, lanes 9-13).
2-O-Ethyl RNA as a new class of antisense compounds
As 2'-O-Methyl RNAs have proven to be efficient antisense
inhibitors (Figure 3), we wondered if an ethyl group at the 2'-O-
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Figure 5. 2'-O-Ethyl-7U 19mer vs. NPEG-2'-O-ethyl-7U 19mer. Lane 1,
unreacted substrate; tone 2, control processing reaction; lane 3, processing reaction
pretreated with magnesium; lanes 4—7, processing after a preincubation with
3, 30, 300, or 3000 fmoles 2'-O-ethyl-7U 19mer; lanes 8 -11 , processing after
a preincubation with 3, 30, 300 or 3000 fmoles NPEG-2'-O-ethyl-7U 19mer;
lanes M, molecular weight standards as in Figure 1.
position might both enhance the stability of the
oligoribonucleotides and increase their binding selectivity.
Therefore, the synthetic procedures that we initially developed
for the preparation of the 2'-O-methyl RNA building blocks were
applied, in a slightly modified form (additional NPE protecive
group on O6 of guanosine), to the synthesis of the 2'-O-
ethylribonucleotide phosphoramidites (16).
Assembly of the 7U 19mer sequence occurred with high
coupling efficiencies (greater than 98%). The standard treatment
of the resin-bound 2'-O-ethyl-7U 19mer with ammonia, which
mediates cleavage from the solid phase and deprotection, results
in an 2'-O-ethyl-7U 19mer that still contains nitrophenylethyl
(NPE) protective groups on the O6 oxygen of the three guanine
bases of 7U 19mer. These additional protective groups are then
removed by DBU/pyridine treatment (20). The resulting fully-
deprotected 2'-O-ethyl-7U 19mer shows a shorter retention time
on reverse phase HPLC compared to the NPE-protected species
(see Fig. 2), but a still longer retention time than the 2'-O-
methyl-7U 19mer compounds (Figure 2). This is consistent with
the expected slightly increased lipophilicity of the 2'-O-ethyl- vs.
the 2'-O-methyl-derivatives.
2-O-Ethyl antisense RNA 19mer versus blocked-G, 2-O-
ethyl antisense RNA 19mer
We tested the behavior of a 2'-O-ethyl-7U 19mer compared to
the 2'-O-ethyl possessing the NPE-protected G residues (Figure
5). The NPE-protected material serves as a control for the
specificity of inhibition. Guanine groups modified with NPE are
no longer able to form G-C base pairs. Since the G residues in
7U 19mer are distributed throughout the interior of the sequence
(see Figure 1), the presence of ^EQ
 residues should block the
hybridization of the inhibitor to the target U7 and hence, block
the inhibition.
We find that the 2'-O-ethyl-7U 19mer inhibits the processing
reaction completely at 300 fmoles and >95% at 30 fmoles. This
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Figure 6. 2'-O-Ethyl inhibition versus 2'-O-methyl inhibition in the presence and
absence of magnesium. Lane 1, control processing reaction; lane 2, processing
reaction pretreated with magnesium; lanes 3—7, processing after a preincubation
with 3, 9, 30, 90or300fmoles2'-O-methyl-7U 19mer; lanes 8-12, processing
after a preincubation with 3, 9, 30, 90 or 300 fmoles 2'-O-ethyl 7U 19mer; lane
13, processing reaction after addition of 30 fmoles 2'-O-methyl-7U 19mer without
magnesium preincubation; lane 14, processing reaction after addition of 30 fmoles
2'-O-ethyl-7U 19mer without magnesium preincubation; lane 15, control
processing reaction; lanes M, molecular weight standards as in Figure 1.
inhibitory activity is similar to that observed with the 2'-O-methyl
compounds (Figure 3). However, the NPE 2'-O-ethyl-7U 19mer
has no inhibitory activity even at the highest levels tested (3
pmoles; Figure 5) demonstrating the role of guanosine base
pairing in the inhibition event.
2'-O-Methyl-7U 19mer vs. 2'-O-ethyl-7U 19mer
A detailed comparison between the inhibitory activity of 2'-O-
methyl-7U 19mer versus 2'-O-ethyl-7U 19mer was performed
(Figure 6). In this experiment the nuclear extract concentration
was decreased to 7.5 /il to allow a more sensitive analysis of
the processing reaction. When the two inhibitors were tested at
3, 9, 30, 90 and 300 fmoles, we found virtually identical
inhibition activity (Figure 6, lanes 3 — 12). A slight modification
of the assay was performed to analyze the inhibitory activity in
the absence of magnesium. When the two inhibitors were added
directly to the extract in the absence of the divalent cation and
the processing substrate RNA was then promptly added in the
presence of 20 mM EDTA, we found that the 2'-O-ethyl inhibitor
is slightly more active (compare in Figure 6, lanes 13 and 14).
However this difference is subtle. Both inhibitors show an
enhancement in their activity at 30 fmoles when preincubated
with the extract plus magnesium (compare lanes 5 and 13 for
the 2'-O-methyl and lanes 10 and 14 for the 2'-O-ethyl).
Quantifying U7 RNA levels in nuclear extracts before and
after inhibitor treatment
There remains the possibility that in the presence of magnesium
both the 2'-O-ethyl and the 2'-O-methyl oligos trigger a
Figure 7. RNase mapping of U7 levels before and after inhibitor treatment. Nuclear
extract samples (7.5 /d) were incubated in buffer D7.5/11.5 containing the indicated
quantities of ssDNA 7U 19mer, 2'-O-cthyl or 2'-O-methyl-7U 19mer or 2'-O-
methyl NS19mer oligoribonucleotides. For samples indicated 'Mg2+> (4, 10-14,
16) the samples included 5 mM MgCl2 and were incubated for 30' on ice, 30'
at room temperature, 30' at 30°C followed by addition of 20 mM EDTA and
the preparation for RNase protection mapping. For the remaining samples (3,
5—9, 15) the ohgonucleotide inhibitor (as indicated) was incubated with the sample
in buffer D7.5/11.5 (which contains 0.13 mM EDTA and no divalent cations)
for 20 minutes on ice followed by addition of 20 mM EDTA and processing
for RNase protection mapping. Mapping was performed with an antisense mouse
U7 RNA probe as described previously (7). Buffer D7.5/11.5 is buffer D diluted
by a factor of 7.5/11.5. Lane 1, TV probe; lane 2, 7U hybridized to 20 /ig tRNA;
lanes 3 and 17, control: extract treated with no oligo, no Mg2"1"; lane 4, extract
treated with Mg2"1"; lane 5, extract treated with 30 pmoles ssDNA 7U 19mer;
lanes 6 and 7, extract treated with 30 and 300 fmoles 2'-O-methyl-7U 19mer;
lanes 8 and 9; extract treated with 30 and 300 fmoles 2'-Oethyl-7U 19mer;
lane 10, extract treated with 30 pmoles ssDNA 7U 19mer plus Mg2"1"; lanes
11 and 12, extract treated with 30 and 300 fmoles 2'-O-roethyl-7U 19mer plus
Mg2+; lanes 13 and 14; extract treated with 30 and 300 fmoles 2'-O-ethyl-7U
19mer plus Mg2"1"; lane 15, extract treated with 3 pmoles control 2'-O-methyl
NS19mer; lane 16, extract treated with 3 pmoles control 2'-O-methyl NS19mer
plus Mg2"1"; lanes M, molecular weight standards as in Figure 1. The truncated
U7 species generated by DNA oligo/RNase H cleavage are indicated (U7-21).
modification (or destruction) of the target U7 sequence which
contribute to the inhibition (similar to RNase H activity with
DNA/RNA hybrids). This may play a role in the irreversibility
of the 2'-O-methyl inhibition seen in Figure 3. Although the
RNA-RNA-like duplex present in a 2'-O-methyl or ethyl-U7
hybrid would not be expected to be a substrate for an enzymatic
degradation of the U7 (such as the DNA-RNA hybrid is for
RNase H), we observed that the preincubation of 2'-O-methyl
or ethyl inhibitors with nuclear extracts in the presence of 5 mM
Mg2* leads to an enhanced inhibition and (with the 2'-O-methyl
RNA) its irreversibility (Figures 3 and 6). To test if a modification
of the U7 RNA had occurred which interferes with the ability
of the U7 RNA to form base pair interactions, we used a sensitive
RNase protection assay to determine the quantity of U7 and its
hybridization capability, both before and after treatment with the
various oligonucleotide inhibitors. After incubation with the
various inhibitors, either in the presence of 5 mM Mg2+, or in
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the absence, the EDTA concentration was raised to 20 mM, the
protein of the sample was destroyed by proteinase K digestion
and the RNA was harvested and hybridized to a radioactive 7U
RNA. Subsequently the sample was treated with RNase A plus
RNase Tl to destroy all non-duplex RNA and the protected RNA
was resolved by gel electrophoresis (Figure 7).
The control, untreated nuclear extract samples display the 63
nt band expected for intact U7 RNA (lanes 3 and 17). Quantitation
of the radioactivity in this band allows us to say that there are
approximately 3 fmoles of U7 RNA in 7.5 /tl of this nuclear
extract. Incubating the extract with Mg2+ alone triggers a mild
reduction in the U7 quantity as well as the appearance of small
amount of a U7 subfragment (Figure 7, lane 4). A small amount
of target destruction of U7 occurs with the DNA 7U 18mer in
the absence of Mg2+ (lane 5) with the U7 destruction complete
when the sample is incubated with 5 mM Mg2+ (lane 10; s ^
also (7) Figure 3). However, there is no detectable alteration in
the U7 RNA with either the 2'-O-methyl-7U 19mer or 2'-O-
ethyl-7U 19mer of the control 2'-O-methyl NS19mer in either
the presence or absence of Mg2+- These are the same conditions
that generate complete inhibition of the histone processing
reaction for the 7U 19mer oligos (see Figure 6). The slight
reduction in U7 levels and the appearance of the U7 subfragment
seen in lanes 11 - 1 4 are no greater than the alterations observed
with Mg2+ incubation in the absence of oligonucleotide (lane 4).
We feel safe in concluding that the potent inhibitory activity of
2'-O-methyl and ethyl oligoribonucleotides is not accompanied
by an enzymatic alteration of the target RNA. However, there
could be subtle alterations in the U7 RNA or the snRNP which
block processing activity that are undetectable by the RNase
protection assay.
DISCUSSION
We are exploring the use of 2'-O-modified oligoribonucleotides
as gene specific inhibitors. We have developed new procedures
for the synthesis of 2'-O-methyl and 2'-O-ethyl protected
ribonucleoside building blocks (16). We demonstrate here that
both 2'-O-methyl and 2'-O-ethyl oligoribonucleotides are superior
to unmodified antisense RNA in inhibiting an RNA processing
event. The inhibition requires only a slight excess of the inhibitor
over the target RNA (approximately 5-fold) and is largely
irreversible under conditions that allow the reversal of a natural
antisense RNA inhibition (see Figure 3). The irreversible nature
of the inhibition does not appear to be accompanied by a
modification in the target RNA such as the adenosine deaminase
activity previously described (34-36). A likely explanation for
this irreversibility may lie, simply, with the reduced degradation
of non-hybridized 2'-O-methyl-RNA in the extract. The presumed
high melting temperature of the inhibitor/U7 hybrid (37) and
difficulty of adding enough complement to the inhibitor to drive
the inhibitor/U7 dissociation reaction makes is nearly impossible
to reverse the binding under physiological conditions. This
irreversibility bodes well for in vivo applications of this class of
inhibitor.
During the course of our work, a publication appeared
demonstrating the advantages of large aliphatic groups at the 2 '-O-
position (31). It was demonstrated that a 2'-O-allyl oligoribo-
nucleotide possesses the nuclease resistance properties of the
2'-O-methyl oligoribonucleotides but in addition, shows an
increase in the level of specific binding to its complement within
a nuclear extract (31). We are currently testing this parameter
with the 2'-O-ethyl derivatives. Furthermore, all of the
experiments reported here have been done with 19mer oligo-
nucleotides, whose calculated hybrid melting temperature is far
above the 30°C used for these inhibitory studies. We are
examining the inhibitory properties of shorter derivatives of both
the ethyl and methyl-modified compounds to determine if shorter
versions of either compound can be useful for the U7 snRNP
inhibition. Of course, our ultimate aim is to use these inhibitors
in vivo, where shorter oligonucleotides may display an advantage
in both target specificity and cell penetration (33).
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